Theravance Biopharma (TBPH) Earns Coverage Optimism Score of 0.12

News stories about Theravance Biopharma (NASDAQ:TBPH) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Theravance Biopharma earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.4389568749194 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

A number of research firms have weighed in on TBPH. Piper Jaffray restated an “overweight” rating and set a $45.00 price objective on shares of Theravance Biopharma in a research report on Thursday. ValuEngine lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub lowered shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 20th. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Leerink Swann upped their target price on shares of Theravance Biopharma from $45.00 to $48.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $42.43.

Theravance Biopharma stock opened at $24.25 on Friday. Theravance Biopharma has a 52-week low of $22.90 and a 52-week high of $43.44. The firm has a market cap of $1,328.83, a PE ratio of -4.45 and a beta of 1.78. The company has a quick ratio of 5.79, a current ratio of 6.05 and a debt-to-equity ratio of 1.94.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.49). Theravance Biopharma had a negative return on equity of 136.86% and a negative net margin of 1,855.42%. The business had revenue of $4.52 million for the quarter, compared to analysts’ expectations of $3.71 million. equities research analysts anticipate that Theravance Biopharma will post -4.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Theravance Biopharma (TBPH) Earns Coverage Optimism Score of 0.12” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2018/03/31/theravance-biopharma-tbph-earns-coverage-optimism-score-of-0-12.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Insider Buying and Selling by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply